[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Gray ST, Chen YL, Lin DT: Efficacy of Proton Beam Therapy in the Treatment of Ewing's Sarcoma of the Paranasal Sinuses and Anterior Skull Base. Skull Base; 2009 Nov;19(6):409-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of Proton Beam Therapy in the Treatment of Ewing's Sarcoma of the Paranasal Sinuses and Anterior Skull Base.
  • Ewing's sarcoma involving the sinonasal cavity and anterior skull base is very rare.
  • The purpose of this article is to present our experience with two such cases, which were both treated with combined chemotherapy and proton beam radiation therapy.
  • The patients were selected from a retrospective medical record analysis that was conducted of all patients who were diagnosed with Ewing's sarcoma of the sinonasal cavity at the Massachusetts Eye & Ear Infirmary/Massachusetts General Hospital Cranial Base Center from 2004 to 2008.
  • One of the patients underwent pretreatment endoscopic subtotal resection to facilitate proton beam radiation therapy.
  • Response to treatment was assessed, post-treatment endoscopic biopsies were performed to assure eradication of disease, and treatment complications were recorded.
  • Both patients completed chemotherapy and proton beam radiation therapy without complication.
  • One patient completed treatment in December 2006 and remains disease free.
  • The second patient completed treatment in March 2007 and remains disease free.
  • Both patients developed headaches accompanied by frontal sinus opacification after treatment that required endoscopic drainage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2006 Jan;19(1):1-8 [16258512.001]
  • [Cites] Cancer. 1976 Nov;38(5):1925-30 [991106.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1996 Oct;105(10):838-43 [8865780.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1407-12 [1517783.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2818-25 [2025847.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):389-95 [1995522.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1664-74 [2213103.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1477-86 [2924256.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):208-13 [2915236.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):23-32 [3334950.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2829-40 [3677016.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1514-24 [2099751.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Jan;69(1):120-7 [2404224.001]
  • [Cites] Recent Results Cancer Res. 1982;80:124-7 [7058276.001]
  • [Cites] Cancer. 1981 May 1;47(9):2204-13 [7226113.001]
  • [Cites] J Bone Joint Surg Br. 1978 Nov;60-B(4):567-74 [711809.001]
  • [Cites] J Bone Joint Surg Am. 1961 Mar;43-A:185-92 [13719331.001]
  • (PMID = 20436842.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2793890
  • [Keywords] NOTNLM ; Ewing's sarcoma / anterior skull base / endoscopic surgery / proton beam
  •  go-up   go-down


2. Campo-Trapero J, Del Romero-Guerrero J, Cano-Sánchez J, Rodríguez-Martín C, Martínez-González JM, Bascones-Martínez A: Relationship between oral Kaposi 's sarcoma and HAART: contribution of two case reports. Med Oral Patol Oral Cir Bucal; 2008 Nov;13(11):E709-13
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between oral Kaposi 's sarcoma and HAART: contribution of two case reports.
  • Two HIV infected patients not receiving Highly Active Antiretroviral Treatment (HAART) presented with epidemic Kaposi's sarcoma of the oral cavity.
  • The other patient developed KS and progressed to AIDS at two years after ceasing HAART due to adverse effects; he was referred to hospital for renewed administration of HAART.
  • In both cases, the lesions observed in the oral cavity were the first clinical manifestation of AIDS.
  • These reports underline the close relationship between the use of HAART and the control of KS lesions, highlighting the important role of the dentist in the identification and early diagnosis of these oral lesions.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. Mouth Neoplasms / etiology. Mouth Neoplasms / prevention & control. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / prevention & control

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978711.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Papamanthos MK, Kolokotronis AE, Skulakis HE, Fericean AM, Zorba MT, Matiakis AT: Acute myeloid leukaemia diagnosed by intra-oral myeloid sarcoma. A case report. Head Neck Pathol; 2010 Jun;4(2):132-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukaemia diagnosed by intra-oral myeloid sarcoma. A case report.
  • Myeloid sarcoma (MS) is a rare extramedullary malignant tumor composed of immature myeloid cells.
  • An unusual case of acute myeloid leukaemia, which was diagnosed by mandibular MS that was developed in the alveolar socket after a dental extraction, is reported.
  • The histological examination (including immunohistochemical analysis) of a subsequent biopsy showed infiltration of the oral mucosa by neoplastic cells.
  • The patient was referred to oncologists that confirmed the initial diagnosis.
  • The patient underwent chemotherapy and the mandibular tumor disappeared.
  • Forty days later, a relapse of the disease, which appeared as a great-ulcerated lesion, was developed in the hard palate.
  • Thirty days after the second chemotherapy had finished, a new intraoral tumor was developed in the vestibular maxillary gingiva.
  • Review of the literature shows no report of intraoral relapse and particularly multiple relapse of a MS that involves the oral cavity.
  • Even though MS is encountered infrequently in the oral cavity, it should be considered in the differential diagnosis of conditions (especially tumors) with a similar clinical appearance.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Etoposide / therapeutic use. Fatal Outcome. Female. Humans. Mouth Mucosa / pathology. Mouth Neoplasms

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 1990 Jul;48(7):748-52 [2193130.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):25-34 [14630077.001]
  • [Cites] J Periodontol. 2003 Oct;74(10):1514-9 [14653399.001]
  • [Cites] Quintessence Int. 2007 Nov-Dec;38(10):817-20 [18197320.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan;105(1):e34-6 [18155599.001]
  • [Cites] Isr Med Assoc J. 2003 Jun;5(6):452 [12841024.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):516-9 [12110349.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Dec;92(6):689-93 [11740487.001]
  • [Cites] Oral Oncol. 2000 Sep;36(5):491-4 [10964059.001]
  • [Cites] Int J Hematol. 2005 Feb;81(2):138-41 [15765782.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Dec;49(12):1346-50 [1955927.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):393-8 [16550530.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):e44-8 [17428693.001]
  • (PMID = 20512638.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide
  • [Other-IDs] NLM/ PMC2878628
  •  go-up   go-down


Advertisement
4. Chuang YM, Hsueh PR, Lee P: Disseminated Streptococcus anginosus infection with empyema thoracis in a patient with sarcoma. J Formos Med Assoc; 2006 Sep;105(9):760-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated Streptococcus anginosus infection with empyema thoracis in a patient with sarcoma.
  • Streptococcus anginosus is a member of the normal flora of the oral cavity and a pathogen of thoracic infection.
  • However, disseminated infection that was identified from different body fluids at the same time has never been reported.
  • We report a 52-year-old man with advanced pulmonary sarcoma who developed neutropenia, bronchopleural fistula and thoracic empyema after chemotherapy.
  • The patient recovered uneventfully after tube drainage and treatment with imipenem.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959625.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / RNA, Ribosomal, 16S; 71OTZ9ZE0A / Imipenem
  •  go-up   go-down


5. Hillyer S, Vicens JC, Levinson H, Bhayani R, Mesea L, Chaudhry R, Fayans E, Fogler R: Alveolar soft-part sarcoma of the tongue in a 17-month-old. Ear Nose Throat J; 2009 Oct;88(10):E4-9
Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar soft-part sarcoma of the tongue in a 17-month-old.
  • Alveolar soft-part sarcoma (ASPS) is a rare and often fatal tumor.
  • ASPS accounts for 5% of all pediatric soft-tissue sarcomas other than rhabdomyosarcomas.
  • In children, ASPS rarely occurs in the oral cavity, and to the best of our knowledge, only 12 cases of ASPS of the tongue occurring during the first decade of life have been previously reported in the literature.
  • Because of the rarity of lingual ASPS in children, no specific treatment protocols have been developed, which makes its management difficult.
  • She was successfully treated with surgical excision without adjuvant radiation or chemotherapy.
  • [MeSH-major] Sarcoma, Alveolar Soft Part / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Radionuclide Imaging. Sodium Pertechnetate Tc 99m. Tomography, X-Ray Computed. Tongue / pathology. Tongue / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19826991.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


6. Gupta S, Gupta OP, Mehrotra S, Mehrotra D: Ewing sarcoma of the maxilla: a rare presentation. Quintessence Int; 2009 Feb;40(2):135-40
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing sarcoma of the maxilla: a rare presentation.
  • Ewing sarcoma is a highly malignant neoplasm, which very rarely involves the head and neck region.
  • A patient presented to the Department of Oral Pathology, Faculty of Dental Sciences, CSM Medical University, Lucknow, India, with a lesion expanding the nasal cavity and posteriorly reaching up to the anterior border of nasopharynx and inferiorly causing the destruction of the hard palate extending into the oral cavity.
  • The biopsy specimen histopathologically revealed undifferentiated malignant neoplasm, and the definitive diagnosis of Ewing sarcoma was made with immunohistochemistry.
  • The patient underwent surgical excision of the lesion followed by radiotherapy and chemotherapy.
  • [MeSH-major] Maxillary Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Cell Adhesion Molecules / analysis. Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness / pathology. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169445.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


7. Srinivasan B, Ethunandan M, Anand R, Hussein K, Ilankovan V: Granulocytic sarcoma of the lips: report of an unusual case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jan;105(1):e34-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the lips: report of an unusual case.
  • Granulocytic sarcoma (GS) is a rare localized, extramedullary tumor composed of immature cells of granulocyte series.
  • It is capable of marked local tissue destruction.
  • This condition can be a precursor of acute myeloid leukaemia by months or years making its diagnosis critical.
  • It is extremely rare in the oral cavity and only 30 cases have been reported in the literature to date and often as a lump in the gingiva, palate, and extraction sockets.
  • [MeSH-major] Lip Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Male. Myelodysplastic Syndromes / complications. Peroxidase / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155599.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  • [Number-of-references] 11
  •  go-up   go-down


8. Choi BS, Baek JH, Shin YM, Kim JH, Kim HW, Lee SJ, Cha HJ: Follicular dendritic cell sarcoma: a case report and review of the literature. Cancer Res Treat; 2010 Jun;42(2):121-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell sarcoma: a case report and review of the literature.
  • Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm that shows a low-to-intermediate malignant potential.
  • The most commonly involved sites are the lymph nodes, but FDCS may also occur at a variety of extranodal sites, including the oral cavity, tonsils, gastrointestinal tract and liver.
  • The patient improved after systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2008 Jan;65(1):1-7 [17658269.001]
  • [Cites] Am J Hematol. 2007 Aug;82(8):725-8 [17373675.001]
  • [Cites] Am J Hematol. 1998 Oct;59(2):161-7 [9766802.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):155-60 [9606806.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):944-55 [8712294.001]
  • [Cites] Am J Clin Pathol. 1995 May;103(5):543-60 [7741099.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):562-72 [2420185.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):294-313 [9010103.001]
  • (PMID = 20622968.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2901081
  • [Keywords] NOTNLM ; Dendritic cell sarcoma / Dendritic cells / Follicular / Lymph nodes
  •  go-up   go-down


9. Whaley JT, Indelicato DJ, Morris CG, Hinerman RW, Amdur RJ, Mendenhall WM, Keole SR, Marcus RB Jr: Ewing tumors of the head and neck. Am J Clin Oncol; 2010 Aug;33(4):321-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Nine patients were diagnosed and treated for Ewing sarcoma of the head and neck at our institution between 1965 and 2007.
  • Primary sites included: mandible (3 patients), calvarium (2 patients), paranasal sinus (2 patients), oral cavity (1 patient), and the extraosseous soft tissue of the neck (1 patient).
  • The median age at diagnosis was 13.0 years (range, 6.3-20.1 years).
  • RESULTS: All patients received multiagent chemotherapy and radiation therapy to a median dose of 55.8 Gy (range, 36-67.2 Gy).
  • CONCLUSIONS: In the context of limited data on head and neck Ewing tumors, combined modality therapy provides excellent local control with reasonable acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841575.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


10. Rocha LA, Rizo VH, Romañach MJ, de Almeida OP, Vargas PA: Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):587-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature.
  • Alveolar soft-part sarcoma (ASPS) is a rare malignant neoplasm with uncertain histogenesis and with a distinctive morphology.
  • It has been described in the oral cavity, but this is the first report of ASPS metastasizing to the maxillary tuber region.
  • A 27-year-old male patient, who was under chemotherapy treatment for ASPS of the thigh, presented in our dental clinic with a painless and pedunculated nodule on the right tuber maxillae.
  • An incisional biopsy was performed and the diagnosis of metastatic ASPS was made.
  • Unfortunately, the patient died 2 months after the diagnosis of the oral metastasis.
  • Metastases of ASPS to the mouth are very rare and indicate a poor prognosis.
  • [MeSH-major] Gingival Neoplasms / secondary. Maxilla / pathology. Sarcoma, Alveolar Soft Part / secondary
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleolus / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Diagnosis, Differential. Fatal Outcome. Gingival Diseases / diagnosis. Granuloma, Giant Cell / diagnosis. Granuloma, Pyogenic / diagnosis. Humans. Male. Muscle Neoplasms / pathology. Thigh / pathology

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303057.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Méndez R, Arnáiz S, Montero M, Tellado M, País E, Ríos J, Vela D: [Clinical patterns of soft-tissue sarcoma in children]. Cir Pediatr; 2001 Jan;14(1):14-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical patterns of soft-tissue sarcoma in children].
  • INTRODUCTION AND OBJECTIVES: Soft tissue sarcomas are rare mesenchymal neoplasms that constitute less than 10% of all pediatric malignancies.
  • Half of these are rhabdomyosarcomas, the remaining 50% have a varied and heterogenous histologic and clinical patterns (fibrosarcoma, synovial cell sarcoma, extraskeletal Ewing's sarcoma, angiosarcoma, liposarcoma, leiomyosarcoma, ...).
  • The purpose of this work is to evaluate our clinical experience with soft tissue sarcomas in uncommon sites over the past 10 years in order to delimitate the prognostic factors in survival and modalities of treatment.
  • MATERIAL AND METHODS: Between 1989 and 1998, 10 patients were diagnosed with soft tissue sarcomas in uncommon sites and treated by us over a total number of 139 pediatric neoplasms (7.19%).
  • Variables investigated included histologic findings, tumor size, age at presentation, primary site, clinical group, radiologic test performed, surgical treatment, radiotherapy and adjuvant chemotherapy, complications and survival rates.
  • RESULTS: The following histologic types of these 10 tumors were identified: 1 hemangiopericytoma in oral cavity, 2 extraosseous Ewing's sarcoma, 1 botryoid rhabdomyosarcoma of the bladder, 1 mediastinal fibrosarcoma, 1 retroperitoneal rhabdomyosarcoma, 1 paratesticular rhabdomyosarcoma, 1 cervical condrosarcoma, 1 alveolar rhabdomyosarcoma and 1 deltoid rhabdomyosarcoma.
  • The mean age at diagnosis was 7 years (4.6 years accounted for rhabdomyosarcoma alone).
  • Adjuvant chemotherapy with IVA was followed by radiotherapy only in four patients.
  • All the children classified in clinical groups II, III or IV needed 2nd. line regimens of chemotherapy.
  • Three patients died in the follow-up instead of the multimodal treatment.
  • 2) radiotherapy will only be necessary if margins of resection cannot control the local disease, and 3) chemotherapy have not clearly demonstrated his benefits as adjuvant therapy in clinical group I lesions but his employ is recommended in all cases because of the poor prognosis due to local recurrence.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11339112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Kao SY, Tu HF, Chang KW, Chang CS, Yang AH, Li WY: Epithelioid sarcoma metastasis to the gingivae: a case report. Int J Oral Maxillofac Surg; 2004 Mar;33(2):205-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma metastasis to the gingivae: a case report.
  • We present a rare case of oral metastatic epithelioid sarcoma rapidly growing over the mandibular gingivae; the primary lesion occurred on the wrist and was treated 18 months earlier by surgery and radiotherapy.
  • The oral metastatic lesion was resected and controlled by chemotherapy.
  • This case has been followed for 2 years with good control of the resected oral metastatic lesion.
  • Histologically, round to oval-shaped tumour cells with abundant eosinophylic globular cytoplasm and eccentrically localized nuclei, lack of epithelial features by electron microscopic study, and the immunohistochemical and cytologic features of tumour cells led into the diagnosis of epithelioid sarcoma.
  • To our knowledge, no reports have been published of its occurrence in the oral cavity
  • [MeSH-major] Gingival Neoplasms / secondary. Sarcoma / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15050080.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


13. Flaitz CM, Nichols CM, Walling DM, Hicks MJ: Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. Oral Oncol; 2002 Jan;38(1):96-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations.
  • Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity.
  • We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm(3) and a viral HIV-RNA polymerase chain reaction (PCR) load of 237 copies/ml, who developed a painful, purple-red mass in the edentulous area of the maxillary right first molar.
  • In addition, the patient was being managed with antiretroviral therapy and liposomal doxorubicin for recurrent cutaneous Kaposi's sarcoma (KS).
  • Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded.
  • Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominantly involves the oral cavity, may mimic KS and has a poor prognosis.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Mouth Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Diagnosis, Differential. Epstein-Barr Virus Infections / complications. Fatal Outcome. HIV Infections / drug therapy. Humans. Male. Middle Aged. Sarcoma, Kaposi / diagnosis


14. Popivanova NI, Chudomirova KN, Baltadzhiev IG, Abadjieva TI: HIV/AIDS-associated Kaposi's sarcoma with multiple skin-mucosal disseminations following ultraviolet (puva) photochemotherapy. Folia Med (Plovdiv); 2010 Jul-Sep;52(3):56-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV/AIDS-associated Kaposi's sarcoma with multiple skin-mucosal disseminations following ultraviolet (puva) photochemotherapy.
  • HIV/AIDS infection in Bulgaria has spread over about 1200 registered patients and it is supposed that the number of the undetected cases is four times higher.
  • Kaposi's sarcoma is rarely observed in our country and no cutaneous-mucosal dissemination is reported for the time being.
  • AIM: The aim of the study is to present a case of disseminated Kaposi's sarcoma in a HIV/ AIDS patient who underwent Psoralen--UVA radiation treatment (PUVA) for total alopecia.
  • Computed axial tomography (CAT) of the visceral organs was also applied.
  • RESULTS: The patient's face, chest, back and upper extremities are covered by more than 50 typical for Kaposi's sarcoma skin tumors and several isolated lesions are found in the oral cavity mucosa.
  • Monitoring of the immune cells and the viral load before and after the application of highly active antiretroviral therapy (HAART) showed CD4+ T cell number = 0.147 x 10(9)/l and VL = 216 000 copies HIV-RNA/ml plasma when the disorder was first detected.
  • In the same time the CD4+ T cell number increased up to 0.255 x 10(9)/l and VL values decreased < 400 c/ml.
  • CONCLUSION: Disseminated form of Kaposi's sarcoma can be provoked by additional immunosuppressive factors like the implementation of PUVA therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. PUVA Therapy / adverse effects. Sarcoma, Kaposi / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. CD4 Lymphocyte Count. Cell Count. HIV / genetics. HIV / immunology. HIV / isolation & purification. Humans. Male. RNA, Viral / analysis. T-Lymphocytes / drug effects. Treatment Outcome. Viral Load


15. Gilaberte M, Gallardo F, Bellosillo B, Saballs P, Barranco C, Serrano S, Pujol RM: Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma. Br J Dermatol; 2005 Oct;153(4):828-32
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma.
  • Plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell lymphoma that often involves the oral cavity of HIV+ patients.
  • We report a 44-year-old man with AIDS and Kaposi sarcoma (KS) previously treated with doxorubicin who, following treatment with highly active antiretroviral therapy, developed an erythematous infiltrated nodule on the right arm.
  • Two years later an infiltrated plaque developed on the abdominal wall.
  • PBL may be seen in patients with transplants or receiving chemotherapy, but is usually observed in patients with advanced AIDS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / complications. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181470.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Chou L: [Clinical and research advances in oral AIDS]. Shanghai Kou Qiang Yi Xue; 2001 Sep;10(3):193-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and research advances in oral AIDS].
  • The majority of HIV-infected patients have HIV-associated oral mucosal lesions at different stages of the disease.
  • In many patients, oral lesions could be the first sign of their HIV infection.
  • Therefore, knowledge of HIV infection has become a critically important requirement for professionals responsible for oral health care delivery and early detection of HIV infection.
  • Oral candidiasis (OC), hairy leukoplakia (HL), and Kaposi sarcoma (KS) are the most common oral lesions strongly associated with HIV infection.
  • Both pseudomembranous and erythematous OC occur in over 95% of HIV-infected patients throughout the oral cavity, highly related to a reversed CD4/CD8 cell ratio.
  • Because of decreased gastric acid secretion in most HIV-infected patients, fluconazole, the antifungal drug that can be absorbed easily despite the gastric pH change, would be the best choice for systemic antifungal treatment.
  • Our latest study indicated that the infection of Epstein-Barr virus (EBV) might not be the definitive criteria for the diagnosis of HL and that the reciprocal activation of EBV and HIV within the epithelium may be the critical event in the development of HL.
  • Our study demonstrated that CD4-bearing oral mucosal Langerhans cells (LC) could be the target of HIV infection, the effector to alter LC number and its antigen processing capability, as well as the vector to pass the virus to submucosal memory T cells, which would be responsible for the second pathway of HIV transmission through mucosal contact with HIV.
  • HIV-associated depletion of LC would lead to impairment of the oral mucosal surveillant system, resulting in opportunistic oral mucosal lesions, such as OC and HL.
  • Because of its reactive type nature clinically and histologically, KS has now been considered a pseudomalignancy.
  • Intralesional injection of cytotoxic drugs has been effective in treatment.
  • Since HIV-infected patients have demonstrated a higher propensity for developing allergic and adverse reactions to antibiotics, bleeding tendency and slow wound healing after dental surgery, decreased levels of neutrophil counts, and xerostomia, a modified dental therapy would be essential for management of HIV-infected dental patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14993986.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  •  go-up   go-down


17. Rafaniello Raviele P, Pruneri G, Maiorano E: Plasmablastic lymphoma: a review. Oral Dis; 2009 Jan;15(1):38-45
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasmablastic lymphoma (PBL) has been recently characterised as an aggressive subtype of non-Hodgkin's lymphoma, most frequently arising in the oral cavity of HIV-infected patients.
  • Similar to other types of AIDS-related lymphomas, there is evidence that Epstein-Barr virus and Kaposi-sarcoma associated Human Herpes Virus 8 may play a relevant role in the pathogenesis of PBL.
  • PBL patients have been treated heterogeneously, with a combination of chemotherapy, radiotherapy and/or surgery, and their prognosis is usually poor, with a death rate of approximately 60% at 1 year.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Epstein-Barr Virus Infections / virology. Gene Rearrangement / genetics. Genes, Immunoglobulin Heavy Chain / genetics. Genes, Immunoglobulin Light Chain / genetics. Herpesvirus 8, Human / physiology. Humans. Sarcoma, Kaposi / virology. Syndecan-1 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939960.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / SDC1 protein, human; 0 / Syndecan-1
  • [Number-of-references] 54
  •  go-up   go-down


18. Govier SM: Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract; 2003 May;18(2):103-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of treatment for mast cell tumors.
  • MCTs located at 'nail bed' (subungual), inguinal/preputial area, and any mucocutaneous area like perineum or oral cavity carry a guarded prognosis and tend to metastasize.
  • The extent of staging procedures following fine-needle aspirate cytologic diagnosis is based on the presence or absence of negative prognostic indicators.
  • Surgery is the treatment of choice for solitary MCTs with no evidence of metastasis.
  • Reponses rates to chemotherapy, (partial response) as high as 78% have been reported, and preliminary evidence suggests that multiagent (prednisone and vinblastine) protocols may confer a higher response rate than single-agent therapy.
  • The diagnosis and staging of MCTs in cats is similar to that in the dog.
  • As with dogs with cutaneous MCTs, surgery is the treatment of choice.
  • Little is known about the effectiveness of adjunctive chemotherapy options for cutaneous MCTs.
  • Adjunctive chemotherapy does not appear to increase survival times.
  • [MeSH-major] Cat Diseases / diagnosis. Dog Diseases / diagnosis. Mast-Cell Sarcoma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12831070.001).
  • [ISSN] 1096-2867
  • [Journal-full-title] Clinical techniques in small animal practice
  • [ISO-abbreviation] Clin Tech Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


19. Otoh EC, Johnson NW, Mandong BM, Danfillo IS: Primary head and neck cancers in Jos, Nigeria: a re-visit. West Afr J Med; 2006 Apr-Jun;25(2):92-100
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common sites for cancer were the eyes (15.4%), lymph nodes (12.4 %), thyroid gland (11.8%) and the oral cavity (7.6%).
  • Carcinomas were most commonly reported in the thyroid gland (19.2%), oral cavity (10.2%) and the eyes (9.5%).
  • Carcinomas were associated with alcohol use and tobacco smoking (p<0.001), while kaposi sarcoma was more associated with HIV-positive patients than squamous cell carcinoma (p=0.016).
  • The duration of symptoms for cancers varied with sites and cancer type but ranged from 6.5-89.7 months (mean= 37.7 +/- 51.1 months).
  • 48 (43.2%) of the treated cancers had primary surgery, while most lymphomas were treated with primary chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918178.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Nigeria
  •  go-up   go-down


20. Otoh EC, Johnson NW, Danfillo IS, Adeleke OA, Olasoji HA: Primary head and neck cancers in North Eastern Nigeria. West Afr J Med; 2004 Oct-Dec;23(4):305-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancer sites were the oral cavity (15.1%) and nasopharynx (11.7%).
  • Carcinomas (68.4 %) were the most common cancers reported, mostly affecting the oral cavity (20.3%).
  • Carcinomas were associated with farmers, kola nut chewers and tobacco users in this region, while kaposi sarcoma was the only cancer associated with HIV-positive patients.
  • 81 % of the staged cancers reported in the stage IV; while treated cancers required primary radiotherapy (51 %) or an adjuvant radical surgery and chemotherapy (9.4%).
  • CONCLUSION: Intra-oral carcinomas were the most common histological types of cancers in the head and neck.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Female. Hospitals, Teaching. Humans. Infant. Infant, Newborn. Lymphoma / epidemiology. Lymphoma / physiopathology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Nigeria / epidemiology. Prevalence. Retinoblastoma / epidemiology. Retinoblastoma / physiopathology. Sarcoma / epidemiology. Sarcoma / physiopathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730089.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Nigeria
  •  go-up   go-down


21. Basić-Jukić N, Bubić-Filipi L, Prgomet D, Djanić Hadzibegović A, Bilić M, Kovac L, Kastelan Z, Pasini J, Mokos I, Basić-Koretić M, Kes P: Head and neck malignancies in Croatian renal transplant recipients. Bosn J Basic Med Sci; 2010 Apr;10 Suppl 1:S37-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demographic data, localization and disease outcome were evaluated in patients who developed cancer.
  • Twenty one patients (1.7%) developed 27 head and neck malignancies.
  • The average time from transplantation to development of cancer was 56.8 months.
  • Of cutaneous malignancies, 88.9% were basal cell carcinoma; one patient had Merkell-cell carcinoma and one patient developed squamous cell carcinoma.
  • Noncutaneous malignancies involved the oral cavity (2 cases of Kaposi's sarcoma and one pharyngeal cancer) and the thyroid gland in 3 patients each.
  • Radical surgery, radiation, and/or chemotherapy were necessary in 33.3% of patients.
  • Immunosuppression was ceased in one patient with Kaposi's sarcoma who returned to dialysis and died 10 years later from heart failure.
  • Careful skin examination and oral examination is mandatory for discovering cancer before dissemination.
  • Sirolimus is safe alternative to calcineurin-based immunosuppression in patients who developed head and neck malignancies.
  • [MeSH-major] Head and Neck Neoplasms / complications. Head and Neck Neoplasms / etiology. Kidney Transplantation / methods. Renal Insufficiency / therapy
  • [MeSH-minor] Brain Neoplasms / complications. Croatia. Follow-Up Studies. Humans. Immunosuppression. Lymphoproliferative Disorders / etiology. Mouth Neoplasms / complications. Skin Neoplasms / complications. Thyroid Neoplasms / complications. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prilozi. 2009 Dec;30(2):175-84 [20087258.001]
  • [Cites] Nephrol Dial Transplant. 1995;10 Suppl 1:74-80 [7617285.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):591-3 [8647617.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Semin Respir Infect. 1993 Sep;8(3):233-9 [8016484.001]
  • [Cites] Transplantation. 1993 Apr;55(4):742-7 [8475546.001]
  • [Cites] Acta Otolaryngol. 2008 Nov;128(11):1255-8 [18607958.001]
  • [Cites] Kidney Int. 2008 Jan;73(1):136 [18084267.001]
  • (PMID = 20433429.001).
  • [ISSN] 1840-4812
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


22. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF: HIV-associated lymphomas and gamma-herpesviruses. Blood; 2009 Feb 5;113(6):1213-24
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease.
  • EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression.
  • (2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Humans. Tumor Virus Infections / pathology. Tumor Virus Infections / therapy. Tumor Virus Infections / virology

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955561.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents
  • [Number-of-references] 162
  •  go-up   go-down


23. Nascimento AF, Fletcher CD: Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol; 2005 Aug;29(8):1106-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The head and neck region, including the oral cavity, parotid gland, nasopharynx, and nasal cavity, was the commonest affected area, accounting for >50% of the cases, followed by retroperitoneum, thigh, leg, subscapular area, hand, vulva, and paratesticular region (1 case each).
  • Treatment modalities included surgery, chemotherapy, and radiation.
  • Two patients died of uncontrolled local disease 13 and 27 months after diagnosis; 4 were alive without disease at 12, 17, 24, and 102 months, including 1 patient with metastasis to 10 of 50 pelvic lymph nodes at presentation; 3 are alive with localized disease at 16, 17, and 19 months; and 1 was followed for 6 months and showed persistent local disease.
  • One patient is alive at 10 months after diagnosis with evidence of metastatic disease to bone, lungs, and breast.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Myogenic Regulatory Factors; 0 / Myoglobin; 0 / S100 Proteins; 0 / myogenic factor 6; 68238-35-7 / Keratins; EC 3.6.4.1 / Myosins
  •  go-up   go-down


24. Rzepecki P, Barzal J, Sarosiek T, Oborska S, Szczylik C: How can we help patients with refractory chronic graft versus host disease- single centre experience. Neoplasma; 2007;54(5):431-6
Genetic Alliance. consumer health - Chronic Graft versus Host Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ocular involvement as well as dermal sclerosis, joint contractures and pathological changes in oral cavity are often refractory to treatment.
  • This kind of patients require complex aggressive immunosuppressive therapy.
  • We are still waiting for drugs against cGVHD, characterized by decreased infectious complications, encouraging efficacy and rare and reversible side effects.
  • We describe eight patients who developed extensive chronic graft versus host disease with eye involvement after alloHSCT.
  • All had ocular manifestations, which were refractory to the first and second line of systemic immunosuppressive therapy.
  • All patients responded to the topical cyclosporine therapy, but clinical improvement was seen only since the fifth month of starting treatment.
  • Other four patients with sclerodermoid type of skin changes, refractory to second line systemic immunosuppressive therapy, were treated with clofazimine.
  • Clofazimine is a drug used to treat leprosy.
  • Because of its anti-inflammatory effects, clofazimine is used also as a second or third line therapy for various skin disorders including: pyoderma gangrenosum, lupus erythematosus, palmoplantar pustulosis and chronic graft versus host disease.
  • All patients,who received clofazimine due to dermal sclerosis, joint contractures and oral manifestations, achieved partial or complete responses and were able to reduce other immunosuppressive drugs.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid / therapy. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Chronic Disease. Clofazimine / therapeutic use. Female. Humans. Male. Middle Aged. Transplantation, Homologous / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688373.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; D959AE5USF / Clofazimine
  •  go-up   go-down


25. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Eilender D, LoRusso P, Thomas L, McCormick C, Rodgers AH, Hooper CL, Tornyos K, Krementz ET, Parker S, Morgan LR: 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Cancer Chemother Pharmacol; 2006 Jun;57(6):719-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers.
  • PURPOSE: This study is to document the activity and acceptability for a new topical agent, A-007, in the treatment of cutaneous metastases from cancer.
  • PATIENTS AND METHODS: This is a multicenter study involving 27 patients with inoperable skin lesions from histologically confirmed cancers of the breast and oral cavity, non-Hodgkin's lymphoma, Kaposi's sarcoma, and angiosarcoma that had failed radiotherapy or systemic treatment.
  • All irritated areas cleared while continuing treatment, and the tumor lesions in the areas of itching also improved.
  • CONCLUSION: A-007, as a 0.25% gel, is confirmed as an effective palliative treatment option for cutaneous metastases from cancers.
  • Skin reactions were minimal, tolerated, and no cessation of treatment was required.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydrazones / therapeutic use. Phenols / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184382.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 49310; United States / NCI NIH HHS / CA / CA 89772
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone; 0 / Antineoplastic Agents; 0 / Hydrazones; 0 / Phenols
  •  go-up   go-down






Advertisement